SCHEDULE 13G/A 0001224962 XXXXXXXX LIVE 1 Ordinary shares, nominal value euro 0.01 per share 09/30/2025 0001756594 Inventiva S.A. 46124U107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Perceptive Advisors LLC b DE 0 7300666 0 7300666 7300666 N 4.99 IA Joseph Edelman b X1 0 7300666 0 7300666 7300666 N 4.99 IN Perceptive Life Sciences Master Fund, Ltd. b E9 0 7300666 0 7300666 7300666 N 4.99 CO Inventiva S.A. 50 rue de Dijon, 21121 Daix France The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Ordinary shares, nominal value euro 0.01 per share (the "Ordinary Shares") of Inventiva S.A. (the "Issuer") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. ("Master Fund") The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003 Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. Y The information required by this Item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported herein are based on 145,951,274 Ordinary Shares outstanding as of October 20, 2025, as disclosed by Inventiva S.A. in its press release dated October 20, 2025, and give effect to the exercise of the Pre-Funded Warrants (as defined below) held by the Master Fund. Neither Perceptive Advisors nor Mr. Edelman directly holds any Ordinary Shares or any Pre-Funded Warrants. The Master Fund holds (i) 6,945,995 Ordinary Shares; (ii) Pre-Funded Warrants exercisable for 5,555,555 Ordinary Shares (the "Pre-Funded Warrants"); and (iii) Tranche 3 Warrants exercisable for 6,666,666 Ordinary Shares (the "Performance Warrants"). The Pre-Funded Warrants may not be exercised if, after giving effect to such exercise, the Reporting Persons' beneficial ownership would exceed 4.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation"). The Performance Warrants are exercisable only upon the Issuer's public release of topline data announcing that any Key Primary Endpoint or Key Secondary Endpoint, with any dosage regimen tested in the trial, has been met no later than June 15, 2027. As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Pre-Funded Warrants for an aggregate of not more than 354,671 Ordinary Shares. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the remaining Pre-Funded Warrants held by them are not exercisable due to the Beneficial Ownership Limitation. The Performance Warrants are currently not exercisable. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such securities. Perceptive Advisors: 4.99% Mr. Edelman: 4.99% Master Fund: 4.99% Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 7,300,666 Mr. Edelman: 7,300,666 Master Fund: 7,300,666 Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 7,300,666 Mr. Edelman: 7,300,666 Master Fund: 7,300,666 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Perceptive Advisors LLC /s/ Joseph Edelman 11/14/2025 Joseph Edelman /s/ Joseph Edelman 11/14/2025 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman 11/14/2025